Johnson & Johnson stock is trading at $256.45, with Wall Street analysts setting a 12-month price target of $283.98, implying 10.7% upside potential. Of 23 analysts covering the pharmaceutical giant, 16 rate it a Buy, 6 Hold, and 1 Sell, citing attractive valuation and favorable sector tailwinds from aging populations. Optimistic and conservative scenarios project JNJ reaching $296.80 or falling to $244.04, respectively, depending on earnings performance and market conditions.
Quwwaa is your AI news butler — a personalized brief and assistant for the stories you care about.
See more on Quwwaa — create a free account